{"pageContent": "Introduction: One fifth of men with newly diagnosed prostate cancer present with locally advanced or metastatic disease. Androgen deprivation therapy (ADT) is the standard systemic therapy in these patients. Despite initial response, essentially all patients will develop castration resistant prostate cancer (CRPC). In this review, we will discuss the revised definitions of CRPC and the latest understanding of the biology of the androgen/androgen receptor axis in the development of advanced prostate cancer.", "metaData": {"source": "Dietary trial in prostate cancer: Early experience and implications for clinical trial design\nhttps://pubmed.ncbi.nlm.nih.gov/11295627/"}}